Related Experiment Video

Updated: Mar 2, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Genomic aberrations in non- small cell lung cancer and their impact on treatment outcome

Amrallah A Mohammed1, Hani El-Tanni2, Mohammed A Alsakkaf3

  • 1Department of Medical Oncology, Faculty of Medicine, Zagazig University, Zagazig, Egypt; Oncology Center, King Abdullah Medical City-Holy Capital, Makkah, Saudi Arabia.

Journal of Cancer Research and Therapeutics
|May 17, 2017
PubMed

Insights

Personalized medicine for nonsmall cell lung cancer (NSCLC) has advanced with the discovery of epidermal growth factor receptor (EGFR) mutations and targeted therapies. Genomic aberrations offer new biomarkers and drug targets for improved NSCLC outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Nonsmall cell lung cancer (NSCLC) treatment has been revolutionized by targeted therapies.
  • The discovery of epidermal growth factor receptor (EGFR) mutations marked a shift towards personalized medicine in NSCLC.
  • Numerous genomic aberrations in NSCLC act as potential predictive biomarkers and therapeutic targets.

Purpose of the Study:

  • To review the molecular pathways implicated in NSCLC.
  • To identify potential therapeutic targets within these pathways.
  • To discuss the impact of these targets on NSCLC disease outcomes.

Main Methods:

  • Literature review of studies on NSCLC molecular pathways.
  • Analysis of genomic aberrations and their role as biomarkers.
  • Synthesis of information on targeted therapies and their clinical impact.

Main Results:

  • EGFR mutations and their targeted inhibitors have significantly improved NSCLC patient outcomes.
  • Other genomic aberrations present diverse therapeutic opportunities.
  • Understanding molecular pathways is crucial for predicting treatment response.

Conclusions:

  • Targeted therapies based on genomic profiling are central to modern NSCLC treatment.
  • Continued research into NSCLC molecular alterations will yield novel biomarkers and drug targets.
  • Personalized medicine strategies are essential for optimizing NSCLC patient care and outcomes.

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

473
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K